The USA truly is a land of innovation. One adult in eight there is currently taking a GLP-1 drug such as Ozempic or Wegovy.1 Within six months, their households spend 5.3% less on groceries and 8%…
The first question before a European launch is not whether the product infringes. It is where, against whom, on what record and on what timetable that question will be tested. Market-entry opinions…
The least reliable line in a European patent portfolio review is the one that looks most reliable. Opted out: yes. The field is binary, the source is public, and the answer takes four seconds to…
The lesson of this year's BIO International Convention in San Diego is not that the market has finally discovered the Unified Patent Court; it has been aware of it for some time. It is that life…
For the past year, European patent lawyers have been discussing the “long arm” of the Unified Patent Court (UPC) as if jurisdiction were simply a question of geographical reach. In cross-border…
Introduction: A Concert InterruptedImagine a Rammstein concert—tight rhythms, explosive precision, and overwhelming power. That’s what many expected from the German divisions of the UPC: efficiency,…
While the patentability of further medical use claim defined by a dosage regimen used to be ruled out, the EPO's Enlarged Board of Appeal has accepted them since decision G 2/08 in 2010. This…
On 16 July 2024, the Munich Central Division revoked a patent for the first time in the litigation between Sanofi, Regeneron, and Amgen (UPC_CFI_1/2023). This decision is important not only because…
Article 124, III of the so-called "PACTE" Law enshrines the disappearance of the statute of limitations for revocation actions concerning industrial property titles. It was intended to put an end to…